These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17548948)

  • 1. [Hepatocellular carcinoma occurring after 11 year-long sustained viral response to interferon therapy for chronic hepatitis C].
    Suganami F; Tomiyama Y; Ohmoto K; Kawase T; Yoshioka N; Shibata N; Yoshida K; Kuboki M; Yamamoto S
    Nihon Shokakibyo Gakkai Zasshi; 2007 Jun; 104(6):809-14. PubMed ID: 17548948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C.
    Takata K; Ishii F; Uchida Y; Fukuda H; Yamauchi R; Umeda K; Tsuchiya N; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
    Intern Med; 2020 Aug; 59(15):1855-1860. PubMed ID: 32350199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C and interferon: fewer cases of liver cancer.
    Prescrire Int; 2013 Jul; 22(140):191. PubMed ID: 23951600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C.
    Kubo S; Nishiguchi S; Tamori A; Hirohashi K; Tanaka H; Tsukamoto T; Shuto T; Kuroki T; Kinoshita H
    Hepatogastroenterology; 2000; 47(34):1100-2. PubMed ID: 11020887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.
    Yoshida Y; Yonezawa M; Okamoto T; Fujiwara Y; Suzuki A; Suzuki Y; Endo K; Kakisaka K; Oikawa T; Kuroda H; Miyasaka A; Takikawa Y
    Clin J Gastroenterol; 2019 Apr; 12(2):120-127. PubMed ID: 30341715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.
    Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: flaws in the cure, or a clue to the flaws?
    Farrell GC
    J Gastroenterol Hepatol; 1999 Sep; 14(9):833-7. PubMed ID: 10535462
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.
    Omata M; Shiratori Y
    J Gastroenterol Hepatol; 2000 May; 15 Suppl():E134-40. PubMed ID: 10921397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.
    Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S
    Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
    Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
    Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.
    Omata M; Yoshida H; Shiratori Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S141-3. PubMed ID: 16234063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon therapy reduces the risk for hepatocellular carcinoma.
    Brown JL
    Gut; 2000 Nov; 47(5):610-1. PubMed ID: 11034573
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
    Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of chronic hepatitis C and prevention of hepatocellular carcinoma.
    Chayama K
    J Gastroenterol; 2002; 37 Suppl 13():69-73. PubMed ID: 12109670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
    J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
    Basso M; Torre F; Picciotto A
    Cancer; 2005 Jun; 103(12):2654-5; author reply 2655. PubMed ID: 15884032
    [No Abstract]   [Full Text] [Related]  

  • 19. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment.
    Chavalitdhamrong D; Tanwandee T
    World J Gastroenterol; 2006 Sep; 12(34):5532-5. PubMed ID: 17006994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.